These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 12483127

  • 41. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [Abstract] [Full Text] [Related]

  • 42. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.
    Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
    [Abstract] [Full Text] [Related]

  • 43. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP.
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [Abstract] [Full Text] [Related]

  • 44. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 45. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 46. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease.
    Tanaka T, Takahama K, Kimura T, Mizuno T, Nagasaka M, Iwata K, Nakano H, Muramatsu M, Takazoe M.
    J Gastroenterol Hepatol; 2006 Jul 10; 21(7):1143-9. PubMed ID: 16824066
    [Abstract] [Full Text] [Related]

  • 47. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T, Iida M, Motoya S, Haruma K, Suzuki Y, Kobayashi K, Ito H, Miyata M, Kusunoki M, Chiba T, Yamamoto S, Hibi T.
    Dis Colon Rectum; 2008 Jun 10; 51(6):916-23. PubMed ID: 18322754
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P.
    Am J Gastroenterol; 2003 Feb 10; 98(2):332-9. PubMed ID: 12591051
    [Abstract] [Full Text] [Related]

  • 50. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P.
    Aliment Pharmacol Ther; 2005 Jul 15; 22(2):101-10. PubMed ID: 16011668
    [Abstract] [Full Text] [Related]

  • 51. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G, Dutch Initiative on Crohn and Colitis (ICC).
    Neth J Med; 2006 Jul 15; 64(7):219-29. PubMed ID: 16929083
    [Abstract] [Full Text] [Related]

  • 52. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP.
    Clin Immunol; 2006 Jan 15; 118(1):11-9. PubMed ID: 16125467
    [Abstract] [Full Text] [Related]

  • 53. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS.
    J Gastroenterol Hepatol; 2010 Apr 15; 25(4):810-6. PubMed ID: 20492339
    [Abstract] [Full Text] [Related]

  • 54. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):351-9. PubMed ID: 16842462
    [Abstract] [Full Text] [Related]

  • 55. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
    Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E.
    Aliment Pharmacol Ther; 2004 Oct 15; 20(8):851-7. PubMed ID: 15479356
    [Abstract] [Full Text] [Related]

  • 56. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb 15; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 57. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr 15; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 58. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.
    Clin Ther; 2011 Jul 15; 33(7):946-64. PubMed ID: 21741088
    [Abstract] [Full Text] [Related]

  • 59. Infliximab dependency in children with Crohn's disease.
    Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P.
    Aliment Pharmacol Ther; 2009 Apr 01; 29(7):792-9. PubMed ID: 19183163
    [Abstract] [Full Text] [Related]

  • 60. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Lédinghen V, Zerbib F.
    Aliment Pharmacol Ther; 2011 Aug 01; 34(4):462-9. PubMed ID: 21671970
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.